Anavex Life Sciences
AVXL | NASDAQ
$0.82
-$0.11 (-12.16%)
At close: Nov 16, 2026, 4:00 PM ET
$0.85
+$0.03 (+3.66%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-12.16%
(1D)No price chart data available for 1D timeframe.
Rating
25.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #908/1021 (Top 89%)
Key Statistics
Market Data
Market Cap $75.79M
1D Range
0.80 0.95
52W Range
0.80 5.30
Valuation (TTM)
PE -3.15
PB 0.67
EV/EBITDA 1.95
Valuation (NTM)
Forward PE 16.11
Forward PEG -0.10
Price Target $11.00
Cash Flow
FCF Yield -44.5%
SBC Adj. FCF Yield -28.8%
SBC Impact -35.4%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 27.1% |
14.7%
FCF 3Y | 5Y -5.5% |
-7.4%
Returns
ROA -10.8%
ROE -11.4%
ROIC -15.4%
Financial Health
Net Cash
$118.33M
Current Ratio 15.62
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leadin...
Sector Healthcare
Industry Biotechnology
Employees 34
IPO Date Aug 2, 2006
Website www.anavex.com
Fiscal Year October - September
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$11.00
Upside
+1241.46%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove AVXL